Inside the research
Zimmer Biomet Holdings, Inc.
ZBH Research profile · latest available data
Price overview
$91.04
▲ +1.35 (+1.5%)
| 52w hi | $103.15 |
|---|---|
| 52w lo | $79.37 |
| Vol | 1.79M |
| As of | 25 Sep 2026 |
The Verdict
Our score +0.20
| Short | -0.03 |
|---|---|
| Medium | +0.31 |
| Long | +0.43 |
computed 2026-09-27
Key fundamentals
Zimmer Biomet Holdings, Inc.
Healthcare · Medical Devices
| Market cap | $17.36B |
|---|---|
| Enterprise value | $24.51B |
| Trailing P/E | 22.10x |
| Forward P/E | 10.04x |
| EV / EBITDA | 9.71x |
| P / S (ttm) | 2.04x |
| Profit margin | 9.5% |
| Return on equity | 6.4% |
| Revenue growth | +4.8% |
| Earnings growth | +33.8% |
| Debt / equity | 60.17 |
Layer Breakdown
| Layer | Raw | Contribution |
|---|---|---|
| Fundamental | +0.31 | |
| Sector | +0.08 | |
| Technical | +0.02 | |
| Earnings | +0.00 | |
| Sentiment | +0.00 |
macro × 1.00 · 2026-09-27
Business overview
Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, upper extremities, and trauma and CMFT products; sports medicine products for the repair of soft tissue injuries, used in the knee and shoulder; and craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open-heart surgery, trauma, or for deformities of the chest. It offers technology and data, bone cement, and surgical products; and a suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, hospitals, healthcare institutions, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. It also offers ROSA Robot, which utilizes robotic technologies to assist a surgeon with implant positioning in total knee arthroplasty or partial knee arthroplasty; and the ZBEdge Platform connects robotic and digital technologies together to collect data before, during and after surgery, that can deliver insights to surgeons to assist in making informed decisions on patient care. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.
Risk Metrics
| Beta vs SPX | 0.29 |
|---|---|
| Corr SPX | 0.16 |
| Annual vol | 29.6% |
| Annual ret | -3.3% |
| Sharpe | -0.11 |
| Max DD | -29.7% |
Window: 504 trading days (504 obs)
Analyst Coverage
| Mean PT | $98.52 |
|---|---|
| High / Low | $130.00 / $83.00 |
| Median | $95.00 |
| Analysts | 21 |
| Strong Buy | 2 | |
|---|---|---|
| Buy | 6 | |
| Hold | 17 | |
| Sell | 1 | |
| Strong Sell | 1 |
Recent rating actions
| 2026-04-29 | Wells Fargo | → Equal-Weight |
| 2026-04-29 | Truist Securities | → Hold |
| 2026-04-29 | Stifel | → Buy |
| 2026-04-29 | JP Morgan | → Neutral |
| 2026-04-29 | Citizens | → Market Outperform |
| 2026-04-29 | Citigroup | → Neutral |
Material Events
| Date | Event | 8-K |
|---|---|---|
| 2026-08-05 | Other Material Event, Exhibits | read |
| 2026-08-05 | Earnings Release, Exhibits | read |
| 2026-06-29 | Material Agreement, Termination of Agreement… | read |
| 2026-05-27 | Shareholder Vote, Exhibits | read |
| 2026-05-12 | Reg FD Disclosure, Exhibits | read |
| 2026-04-28 | Officer / Director Change, Reg FD Disclosure… | read |
| 2026-04-28 | Earnings Release, Exhibits | read |
| 2026-02-10 | Earnings Release, Exhibits | read |
| 2026-01-12 | Officer / Director Change, Exhibits | read |
| 2025-11-05 | Earnings Release, Exhibits | read |
| 2025-10-07 | Other Material Event, Exhibits | read |
| 2025-09-04 | Other Material Event | read |
Insider Trades
| Date | Insider | Role | Action | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-01 | Thornal Kevin R | Officer, Grp Pres-Global | Option exercise | 9.96K | — |
| 2026-08-01 | Thornal Kevin R | Officer, Grp Pres-Global | Withheld for tax | 4.27K | $395.37K |
Flow & Concentration
| Insider 180d net | $0 |
|---|---|
| Insider buys / sells | 0 / 0 |
| Insider bias | Neutral |
| 13F holders | 8 |
| Top-5 share | 99.5% |
| HHI | 3,924 (concentrated) |
Top Holders
| Holder | Value | Shares |
|---|---|---|
| State Street Corp | $766.34M | 8.88M |
| Citadel Advisors | $316.10M | 3.67M |
| Capital Research / Capital World | $237.49M | 2.76M |
| AQR Capital Management | $31.29M | 367.37K |
| Millennium Management | $19.12M | 222.06K |
| Fidelity / FMR LLC | $3.93M | 45.69K |
| Bridgewater Associates | $3.11M | 36.15K |
| T. Rowe Price Group | $412.99K | 4.80M |
As of 2026-06-30
Dividends
| Yield (TTM) | 0.79% |
|---|---|
| $ / share (TTM) | $0.72 |
| 5y CAGR | +0.6% |
Annual dividend per share
| 2021 | $0.93 |
|---|---|
| 2022 | $0.96 |
| 2023 | $0.96 |
| 2024 | $0.96 |
| 2025 | $0.96 |
| 2026 | $0.24 |
SEC Filings
The Long Run
FY 2009–2025 · 17 years
| Line | Latest | CAGR | Trend |
|---|---|---|---|
| Revenue | $7.39B | +3.7% | |
| Gross profit | $1.21B | -8.0% | |
| Operating income | $1.10B | +0.5% | |
| Net income | $1.02B | +2.2% | |
| Cash from ops | $1.58B | +3.9% |
Indices
Recent Sessions
| Date | Open | High | Low | Close | Vol |
|---|---|---|---|---|---|
| Sep 25 | $89.43 | $91.84 | $89.24 | $91.04 | 1.79M |
| Sep 24 | $91.43 | $92.51 | $89.02 | $89.69 | 2.65M |
| Sep 23 | $92.60 | $93.25 | $89.87 | $90.88 | 2.97M |
| Sep 22 | $95.43 | $95.47 | $93.36 | $93.98 | 1.71M |
| Sep 21 | $95.32 | $95.66 | $93.64 | $94.32 | 1.60M |
Understand the score. Research layers are inputs to a model, and the available data has limits.
Read the methodology →